Valmark Advisers Inc. Sells 69 Shares of Becton, Dickinson and Company $BDX

Valmark Advisers Inc. cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.5% in the 2nd quarter, Holdings Channel reports. The firm owned 2,702 shares of the medical instruments supplier’s stock after selling 69 shares during the period. Valmark Advisers Inc.’s holdings in Becton, Dickinson and Company were worth $465,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock valued at $2,880,510,000 after acquiring an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after acquiring an additional 667,957 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Becton, Dickinson and Company by 7.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock valued at $1,012,649,000 after acquiring an additional 312,124 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier’s stock valued at $707,872,000 after acquiring an additional 37,733 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $189.06 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The business has a 50-day moving average price of $189.87 and a two-hundred day moving average price of $186.61. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a market cap of $54.19 billion, a P/E ratio of 34.00, a PEG ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period last year, the business posted $3.50 EPS. The business’s revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BDX shares. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday. Piper Sandler restated a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $205.40.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.